Overview
Sodium Sulfate Anhydrous is the anhydrous, sodium salt form of sulfuric acid. Sodium sulfate anhydrous disassociates in water to provide sodium ions and sulfate ions. Sodium ion is the principal cation of the extracellular fluid and plays a large part in the therapy of fluid and electrolyte disturbances. Sodium sulfate anhydrous is an electrolyte replenisher and is used in isosmotic solutions so that administration does not disturb normal electrolyte balance and does not lead to absorption or excretion of water and ions.
Indication
indicated for bowel cleansing prior to colonoscopy or barium enema X-ray examination.
Associated Conditions
No associated conditions information available.
Clinical Trials
Title | Posted | Study ID | Phase | Status | Sponsor |
|---|---|---|---|---|---|
2023/05/26 | Phase 2 | Not yet recruiting | |||
2009/03/10 | Phase 2 | Terminated |
FDA Drug Approvals
Approved Product | Manufacturer | NDC Code | Route | Strength | Effective Date |
|---|---|---|---|---|---|
| Ascend Laboratories, LLC | 67877-725 | ORAL | 17.5 g in 177 mL | 3/28/2023 | |
| Lupin Pharmaceuticals,Inc. | 43386-090 | ORAL | 22.74 g in 274.31 g | 12/20/2016 | |
| Deseret Biologicals, Inc. | 43742-2108 | ORAL | 6 [hp_X] in 1 mL | 5/27/2025 | |
| Martin & Pleasance Pty Ltd | 84999-029 | ORAL | 6 [hp_X] in 1 1 | 9/9/2025 | |
| Novel Laboratories, Inc. | 40032-090 | ORAL | 22.74 g in 274.31 g | 2/8/2023 | |
| Strides Pharma Science Limited | 64380-116 | ORAL | 17.5 g in 177 mL | 1/17/2024 | |
| Taro Pharmaceuticals U.S.A., inc. | 51672-4170 | ORAL | 17.5 g in 177 mL | 4/2/2024 | |
| Lupin Pharmaceuticals,Inc. | 43386-060 | ORAL | 22.72 g in 278.26 g | 9/10/2025 | |
| Novel Laboratories, Inc. | 40032-060 | ORAL | 22.72 g in 278.26 g | 11/18/2009 | |
| Braintree Laboratories, Inc. | 52268-112 | ORAL | 13.13 g in 133.1 mL | 8/18/2020 |
EMA Drug Approvals
Approved Product | Authorization Holder | Status | Issued Date |
|---|---|---|---|
| No EMA approvals found for this drug. | |||
HSA Drug Approvals
Approved Product | Manufacturer | Approval Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| FORTRANS FOR ORAL SOLUTION | SIN09234P | GRANULE, FOR SOLUTION | 5.7 g | 3/3/1997 |
NMPA Drug Approvals
Approved Product | Company | Approval Number | Drug Type | Dosage Form | Approval Date |
|---|---|---|---|---|---|
| No NMPA approvals found for this drug. | |||||
PPB Drug Approvals
Approved Product | Registration No. | Company | Licence No. | Strength | Registration Date |
|---|---|---|---|---|---|
| ISOCOLAN POWDER FOR ORAL SOLUTION | N/A | N/A | N/A | 8/19/2024 |
TGA Drug Approvals
Approved Product | ARTG ID | Sponsor | Registration Type | Status | Registration Date |
|---|---|---|---|---|---|
| Blackmores Celloids S.S.69 Tablets | 20228 | Medicine | A | 10/14/1991 | |
| MOVIPREP ORANGE powder for oral solution sachet | 206448 | Medicine | A | 2/27/2013 | |
| PREPKIT ORANGE powder for oral liquid sachet composite pack | 370153 | Medicine | A | 6/24/2021 | |
| Young Living Alkalime | 294029 | Medicine | A | 9/18/2017 | |
| GLYCOPREP ORANGE powder for oral liquid sachet | 370152 | Medicine | A | 6/24/2021 | |
| LYMPHOMYOSOT | 440431 | Medicine | A | 2/9/2024 | |
| DENDY Colonlytely Powder | 30138 | Medicine | A | 10/25/1991 | |
| Active Elements Active 4.2 Tablets | 127004 | Medicine | A | 4/18/2006 | |
| BLACKMORES DUO CELLOIDS S.S.P.C. Tablets | 20302 | Medicine | A | 10/14/1991 | |
| MOVIPREP powder for oral solution sachet | 155398 | Medicine | A | 9/25/2008 |
Health Canada Drug Approvals
Approved Product | Company | DIN | Dosage Form | Strength | Market Date |
|---|---|---|---|---|---|
| LYPHOSOT - TAB | 02229577 | Tablet - Oral | 4 D | 10/11/1996 | |
| OCL SOLUTION | ABBOTT LABORATORIES, LIMITED | 00709298 | Solution - Oral | 5.68 MG / ML | 12/31/1988 |
| BI-PEGLYTE | pendopharm division of pharmascience inc | 02326302 | Tablet (Delayed-Release)
,
Powder For Solution
,
Kit - Oral | 5.74 G / SACHET | 6/6/2010 |
| PEGLYTE POWDER | pendopharm division of pharmascience inc | 00777838 | Powder For Solution - Oral | 22.96 G / BOTTLE | 12/31/1988 |
| CONSI-BOSAN B51 - LIQ. | professional health products | 02151391 | Liquid - Oral | 4 D / ML | 12/31/1996 |
| NATRIUM SULFURICUM - INJEEL LIQ (12D,30D,200D/1.1ML) | 02066602 | Liquid - Oral | 12 D / 1.1 ML | 12/31/1994 | |
| ZIEF HOMOEOPATHIC TAB | new era lab c/o seven seas | 00578630 | Tablet - Oral | 6 X / TAB | 12/31/1983 |
| NATRUM SULF GRANULE 1DH | homeocan inc. | 00859109 | Tablet - Oral | 1 DH / DH | 12/31/1990 |
| NATRUM SULFURICUM GRANULE 1DH - 30CH | dolisos laboratoires s.a. | 00700169 | Tablet - Oral | 1 DH / DH | 12/31/1987 |
| HEPTOX | bio active canada ltd. | 02233624 | Liquid - Oral | 12 X | 5/26/1998 |
CIMA AEMPS Drug Approvals
Approved Product | Company | Registration Number | Pharmaceutical Form | Prescription Type | Status |
|---|---|---|---|---|---|
| No CIMA AEMPS (Spain) approvals found for this drug. | |||||
Philippines FDA Drug Approvals
Approved Product | Company | License Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| No Philippines FDA approvals found for this drug. | |||||
Saudi SFDA Drug Approvals
Approved Product | Company | License Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| No Saudi SFDA approvals found for this drug. | |||||
Malaysia NPRA Drug Approvals
Approved Product | Company | Registration Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| No Malaysia NPRA approvals found for this drug. | |||||
UK EMC Drug Information
Medicine Name | MA Holder | MA Number | Pharmaceutical Form | Active Ingredient | Authorization Date |
|---|---|---|---|---|---|
| No UK EMC drug information found for this drug. | |||||
Help Us Improve
Your feedback helps us provide better drug information and insights.